Cart
sales@molnova.com
SCH28080
CAS No. 76081-98-6
SCH28080( —— )
Catalog No. M21900 CAS No. 76081-98-6
SCH28080 is a reversible, K+-competitive inhibitor of the gastric (H+/K+)-ATPase, with a Ki of 0.12 μM. SCH28080 is an effective inhibitor of acid secretion in vivo and with anti-gastric ulcer activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 101 | In Stock |
|
| 10MG | 149 | In Stock |
|
| 25MG | 251 | In Stock |
|
| 50MG | 374 | In Stock |
|
| 100MG | 534 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSCH28080
-
NoteResearch use only, not for human use.
-
Brief DescriptionSCH28080 is a reversible, K+-competitive inhibitor of the gastric (H+/K+)-ATPase, with a Ki of 0.12 μM. SCH28080 is an effective inhibitor of acid secretion in vivo and with anti-gastric ulcer activity.
-
DescriptionSCH28080 is a reversible, K+-competitive inhibitor of the gastric (H+/K+)-ATPase, with a Ki of 0.12 μM. SCH28080 is an effective inhibitor of acid secretion in vivo and with anti-gastric ulcer activity.
-
In VitroSCH28080 competitively inhibits the K+-stimulated hydrolysis of ATP, with a Ki of 0.12 μM .SCH28080 inhibits histamine-induced [14C]aminopyrine uptake into isolated rabbit parietalcells with an IC50 of 0.029 μM.SCH28080 causes a dose-dependent reduction in cell viability with IC50 values of 22.9 μM and 15.3 μM after 2 h and 24 h treatments, respectively, and cell viability was below 10% at 100 μM already after 2 h treatment.SCH28080 induces apoptosis and is cytotoxic at higher doses.SCH28080 inhibits insulin secretion by activation of IK ATP and inhibition of L-type voltage-gated Ca2+ channels, reduces cell viability and dose-dependently induces apoptosis/necrosis. Cell Viability Assay Cell Line:INS-1E cell Concentration:3.1 μM, 6.25 μM, 12.5 μM, 25 μM, 50 μM, 100 μM Incubation Time:2 hours, 24 hours Result:Caused a dose-dependent reduction in cell viability.
-
In VivoSCH28080 (20 mg/kg; i.p.) inhibits gastric ulcers induced by pylorusligation in rats. Animal Model:Male Wistar rat (280-350 g), the Shay rat modelDosage:20 mg/kg Administration:Intraperitoneal injection Result:Showed 91% inhibition on gastric ulcers induced by pylorusligation in rats.
-
Synonyms——
-
PathwayMembrane Transporter/Ion Channel
-
TargetProton Pump
-
RecptorKi: 0.12μM ((H+/K+)-ATPase)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number76081-98-6
-
Formula Weight277.32
-
Molecular FormulaC??H??N?O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (360.59 mM)
-
SMILESN#CCC1=C(C)N=C2C(OCC3=CC=CC=C3)=CC=CN21
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Scott CK, et al. Studies on the mechanism of action of the gastric microsomal (H+ + K+)-ATPase inhibitors SCH 32651 and SCH 28080. Biochem Pharmacol. 1987 Jan 1;36(1):97-104.
2. Martin Jakab, et al. The H+/K+ ATPase Inhibitor SCH-28080 Inhibits Insulin Secretion and Induces Cell Death in INS-1E Rat Insulinoma Cells. Cell Physiol Biochem. 2017;43(3):1037-1051.
3. Y Hamagishi, et al. Inhibitory Effects of Copiamycin A, a Macrocyclic Lactone Antibiotic, on Gastric H+,K(+)-ATPase, Acid Secretion and Ulcer Formation. Jpn J Pharmacol. 1991 Feb;55(2):283-6.
molnova catalog
related products
-
Esomeprazole magnesi...
A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells.
-
Pantoprazole
A proton pump inhibitor that inhibits gastric acid secretion; works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.
-
Revaprazan
Revaprazan (SB-641257;YH-1885) is a potent potassium-competitive acid blocker (P-CAB) that inhibits H+,K+-ATPase in a reversible and K+-competitive manner.
